Ezose Sciences Receives Grant from Michael J. Fox Foundation
News Feb 20, 2014
Ezose’s Glycan Map technology enables automated analysis of glycans, which attach to proteins in the body and affect their biochemical function. The speed, scope, and quantitative power of this technology ho ld the potential for discovering novel glycan changes associated with altered protein function during the onset and progression of wide - ranging diseases, including Parkinson’s disease and other neurological disorders. Glycan s could serve as novel biomarkers for guiding clinical management and drug development and provide insight into disease mechanism and novel drug targets.
The research funded by the foundation will be performed in Ezose’s laboratories, where the Glycan Map assay will be used to compare glycan profiles in brain - stem tissue from rat models of Parkinson’s disease and control rats over time and with respect to development of symptoms.
“The Michael J. Fox Foundation has brought a tireless sense of urgency to advancing research in to Parkinson’s disease,” said Ryuichi Kiyama, Ph.D., Chairman and Chief Executive Officer of Ezose. “We look forward to bringing that spirit as well as our technical capabilities to this novel research project.”
Mark Frasier, Ph.D., Vice President of Research Programs at The Michael J. Fox Foundation, commented: “Two important steps toward the development of a disease - modifying therapy for Parkinson’s are greater understanding of the underlying pathology of the disease and validation of a reliable biomarker. Ezose’s glycan analysis offers a new approach to serve those goals and bring us closer to a Parkinson’s cure.”
LogicTRN Model Illuminates Regulatory Gene FrameworkNews
A newly devised algorithm called LogicTRN has the potential to unravel the complexities of genetic regulation.READ MORE
Protein's Role in Mitochondrial Metabolism IdentifiedNews
EXD2, a protein previously thought to be localised to the nucleus, has a key role in the production of proteins by mitochondria.READ MORE
Glythera Appoints Chief Scientific Officer and Strengthens SABNews
Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates. Dr Jon Roffey appointed to Scientific Advisory Board.READ MORE